Simplex Trading
IMDX

Simplex Trading’s Insight Molecular Diagnostics IMDX Stock Holding History

Simplex Trading’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.94K Hold
1,200
– – ﹤0.01% 8039
2025
Q4 		$9K Buy
+1,200
New +$6.77K ﹤0.01% 7053
2022
Q4 		– Sell
-2,330
Closed -$34K – 10048
2022
Q3 		$34K Hold
2,330
– – ﹤0.01% 6928
2022
Q2 		$41K Buy
2,330
+2,120
+1,010% +$48.2K ﹤0.01% 6738
2022
Q1 		$6K Sell
210
-125
-37% -$4K ﹤0.01% 9310
2021
Q4 		$14K Buy
335
+125
+60% +$7.19K ﹤0.01% 8757
2021
Q3 		$24K Hold
210
– – ﹤0.01% 8276
2021
Q2 		$24K Buy
210
+208
+10,400% +$20.3K ﹤0.01% 8432
2021
Q1 		$21K Sell
2
-1
-33% -$95 ﹤0.01% 7419
2020
Q4 		$12K Buy
+3
New +$110 ﹤0.01% 7301
2020
Q3 		– Sell
-1
Closed -$1K – 8275
2020
Q2 		$1K Buy
+1
New +$52 ﹤0.01% 7387
2020
Q1 		– Hold
0
– – – 7381

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Simplex Trading's IMDX Position: Q1 2023 in Review

Simplex Trading sold out of Insight Molecular Diagnostics (IMDX) in Q1 2023, closing a stake of 1 share.

Simplex Trading first reported a position in IMDX in Q1 2019 and held it in 12 quarters. The position peaked at $43K in Q4 2020. 52 funds tracked by Wall St. Rank hold IMDX as of Q1 2023.

  • Simplex Trading reported no remaining Insight Molecular Diagnostics position as of Q1 2023 after selling out during the quarter.
  • Simplex Trading sold 1 Insight Molecular Diagnostics share in Q1 2023.
  • Simplex Trading first reported a position in Insight Molecular Diagnostics in Q1 2019 and held it in 12 quarters.
  • Simplex Trading's Insight Molecular Diagnostics position peaked at $43K in Q4 2020.
  • 52 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2023.

Based on Simplex Trading's 13F filing for Q1 2023, filed 27 Apr 2023.